ABB.CH

65.34

+0.83%↑

ADEN.CH

18.3

-1.13%↓

OERL.CH

3.74

+0.54%↑

ABB.CH

65.34

+0.83%↑

ADEN.CH

18.3

-1.13%↓

OERL.CH

3.74

+0.54%↑

ABB.CH

65.34

+0.83%↑

ADEN.CH

18.3

-1.13%↓

OERL.CH

3.74

+0.54%↑

ABB.CH

65.34

+0.83%↑

ADEN.CH

18.3

-1.13%↓

OERL.CH

3.74

+0.54%↑

ABB.CH

65.34

+0.83%↑

ADEN.CH

18.3

-1.13%↓

OERL.CH

3.74

+0.54%↑

Search

DKSH Holding AG

Slēgts

SektorsRūpniecība

58.3 1.92

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

57.1

Max

58.5

Galvenie mērījumi

By Trading Economics

Ienākumi

19M

111M

Pārdošana

21M

5.5B

P/E

Sektora vidējais

18.846

61.065

EPS

1.41

Dividenžu ienesīgums

4.21

Peļņas marža

2.002

Darbinieki

24,799

EBITDA

53M

246M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+28.05% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

4.21%

2.23%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-253M

3.8B

Iepriekšējā atvēršanas cena

56.38

Iepriekšējā slēgšanas cena

58.3

Ziņu noskaņojums

By Acuity

100%

0%

394 / 406 Rangs Industrials

DKSH Holding AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. marts 23:47 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

2026. g. 23. marts 22:55 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

2026. g. 23. marts 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 23. marts 23:59 UTC

Tirgus saruna

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

2026. g. 23. marts 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

2026. g. 23. marts 23:37 UTC

Tirgus saruna

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 23. marts 22:42 UTC

Tirgus saruna
Galvenie ziņu notikumi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

2026. g. 23. marts 22:40 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

2026. g. 23. marts 22:23 UTC

Tirgus saruna

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

2026. g. 23. marts 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

2026. g. 23. marts 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

2026. g. 23. marts 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

2026. g. 23. marts 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

2026. g. 23. marts 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

2026. g. 23. marts 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

2026. g. 23. marts 22:08 UTC

Tirgus saruna

Ebos Needs to Reset Its Gearing Targets -- Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 23. marts 21:42 UTC

Tirgus saruna

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

2026. g. 23. marts 21:32 UTC

Peļņas

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

2026. g. 23. marts 21:10 UTC

Galvenie ziņu notikumi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 23. marts 20:50 UTC

Tirgus saruna
Peļņas
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

DKSH Holding AG Prognoze

Cenas mērķis

By TipRanks

28.05% augšup

Prognoze 12 mēnešiem

Vidējais 73.5 CHF  28.05%

Augstākais 75 CHF

Zemākais 72 CHF

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi DKSH Holding AG — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

2

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

394 / 406 Rangs Rūpniecība

Ziņu noskaņojums

Ļoti spēcīga liecība "Lāču" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par DKSH Holding AG

DKSH Holding AG provides various market expansion services in Thailand, Greater China, Malaysia, Singapore, rest of the Asia Pacific, and internationally. The company offers sourcing, market insights, marketing, sales, eCommerce, distribution, logistics, and after-sales services. It operates through four segments: Healthcare, Consumer Goods, Performance Materials, and Technology. The Healthcare segment provides various services, such as registration, regulatory, market entry studies, importation, customs clearance, marketing and sales, physical distribution, invoicing, and cash collection services for ethical pharmaceuticals, consumer health, and over-the-counter health products, as well as medical devices. The Consumer Goods segment offers a range of services, including product feasibility studies, registration, importation, customs clearance, marketing and merchandising, sales, warehousing, physical distribution, invoicing, cash collection, and after-sales services for fast moving consumer goods, food services, luxury goods, and fashion and lifestyle products, as well as hair and skin cosmetics. The Performance Materials segment sources, markets, and distributes a range of specialty chemicals and ingredients for the pharmaceutical, personal care, food and beverage, and industrial applications, as well as provides market expansion services for performance materials. The Technology segment offers market expansion services comprising a range of capital investment goods and analytical instruments in the areas of infrastructure, industrial materials and supplies, precision and textile machinery, semiconductors, photovoltaic and electronics, agriculture, and hospitality, as well as specialized industrial applications. The company was founded in 1865 and is based in Zurich, Switzerland.
help-icon Live chat